Microbiome/transforming growth factor-β axis as a diagnostic and therapeutic target for MASLD in Egyptian patients

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading cause of chronic hepatic disorders worldwide. Gut microbiome dysbiosis influences MASLD pathogenesis via the gut–liver axis. This study investigated gut microbiome alterations, biochemical markers, and their diagnostic potential in MASLD. A case control study included 60 Egyptian adults (30 MASLD patients, 30 healthy controls) who underwent comprehensive biochemical profiling and quantitative real-time polymerase chain reaction (qRT-PCR) analysis of selected gut microbiota from fecal samples. Antioxidant biomarkers, including superoxide dismutase (SOD) and malondialdehyde (MDA), were measured spectrophotometrically, while mRNA expression of nuclear factor erythroid 2-related factor 2 (NRF2), transforming growth factor-beta (TGF-β), and signal transducer and activator of transcription 3 (STAT3) was assessed by reverse transcription PCR (RT-PCR). The fibrosis index (FIB-4) was calculated, and diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curves. MASLD patients displayed marked microbiome dysbiosis, with significant enrichment of Bacteroides (p < 0.001) and depletion of Bifidobacterium (p < 0.005). TGF-β expression was significantly elevated (p < 0.001) and demonstrated excellent diagnostic performance (area under the curve [AUC] = 0.956; sensitivity = 100%; specificity = 83.3%). MDA, FIB-4, and NRF2 showed moderate accuracy, while Bacteroides (AUC = 0.744) and Bifidobacterium (AUC = 0.683) also provided discriminatory value. Bacteroides correlated positively with total cholesterol, whereas Bifidobacterium correlated inversely. Collectively, elevated TGF-β, increased Bacteroides, and reduced Bifidobacterium highlight promising diagnostic and therapeutic targets in MASLD. These findings emphasize the mechanistic role of the gut–liver axis and support microbiome-informed roles for early detection and management.

Authors

Institutions

Publication Details

Journal
Gut Pathogens
Published
2026-04-11
DOI
https://doi.org/10.1186/s13099-026-00826-4
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Microbiome/transforming growth factor-β axis as a diagnostic and therapeutic target for MASLD in Egyptian patients

Amany Marwan, Laila A. Eissa, Omar Ahmed Elmetwally, Shimaa A. Abass et al.
Gut Pathogens
Parathyroid Disorders and Treatments
article

Microbiome/transforming growth factor-β axis as a diagnostic and therapeutic target for MASLD in Egyptian patients

Amany Marwan, Laila A. Eissa, Omar Ahmed Elmetwally, Shimaa A. Abass, Mohamed M. A. El-Sokkary, Mohamed M. Marwan
article en

Abstract

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading cause of chronic hepatic disorders worldwide. Gut microbiome dysbiosis influences MASLD pathogenesis via the gut–liver axis. This study investigated gut microbiome alterations, biochemical markers, and their diagnostic potential in MASLD. A case control study included 60 Egyptian adults (30 MASLD patients, 30 healthy controls) who underwent comprehensive biochemical profiling and quantitative real-time polymerase chain reaction (qRT-PCR) analysis of selected gut microbiota from fecal samples. Antioxidant biomarkers, including superoxide dismutase (SOD) and malondialdehyde (MDA), were measured spectrophotometrically, while mRNA expression of nuclear factor erythroid 2-related factor 2 (NRF2), transforming growth factor-beta (TGF-β), and signal transducer and activator of transcription 3 (STAT3) was assessed by reverse transcription PCR (RT-PCR). The fibrosis index (FIB-4) was calculated, and diagnostic accuracy was evaluated using receiver operating characteristic (ROC) curves. MASLD patients displayed marked microbiome dysbiosis, with significant enrichment of Bacteroides (p < 0.001) and depletion of Bifidobacterium (p < 0.005). TGF-β expression was significantly elevated (p < 0.001) and demonstrated excellent diagnostic performance (area under the curve [AUC] = 0.956; sensitivity = 100%; specificity = 83.3%). MDA, FIB-4, and NRF2 showed moderate accuracy, while Bacteroides (AUC = 0.744) and Bifidobacterium (AUC = 0.683) also provided discriminatory value. Bacteroides correlated positively with total cholesterol, whereas Bifidobacterium correlated inversely. Collectively, elevated TGF-β, increased Bacteroides, and reduced Bifidobacterium highlight promising diagnostic and therapeutic targets in MASLD. These findings emphasize the mechanistic role of the gut–liver axis and support microbiome-informed roles for early detection and management.

Gut PathogensVol. 18(1)
Damietta University (EG), Kafrelsheikh University (EG), Mansoura University (EG), Mansoura University Hospital (EG)
Mansoura University
Zero hunger
Openalex Percentile: Top 26%
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.